FindTrial
Sign In

Precision Immunology to Determine the Immune Response in Patients With COVID-19

Precision Immunology Approach to Better Understand the Divergent Host Responses Towards Infection With SARS-CoV-2

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04360733
Enrollment
200
Registered
2020-04-24
Start date
2020-04-20
Completion date
2022-09-30
Last updated
2021-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, SARS-CoV 2

Brief summary

To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts

Interventions

OTHERBlood draw

serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis

Sponsors

University of Bonn
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* SARS-Cov2 positive PCR

Exclusion criteria

* pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Immune response4 weeksImmune response of whole blood stimulation assay with various immune activators will be measured by FACS and multiplex Assay

Countries

Germany

Contacts

Primary ContactChristian Bode, MD
christian.bode@ukbonn.de+49228287
Backup ContactFolkert Steinhagen, MD
Folkert.Steinhagen@ukbonn.de+49228287

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026